LifeOS Genomics
Hsinchu, Taiwan· Est.
Taiwan‑based IVD firm delivering ultra‑sensitive multiplex liquid‑biopsy diagnostics via its mdPCR‑based QLoci platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan‑based IVD firm delivering ultra‑sensitive multiplex liquid‑biopsy diagnostics via its mdPCR‑based QLoci platform.
OncologyPrenatalInfectious Disease
Technology Platform
Multiplex digital PCR (mdPCR) that combines partitioned PCR with molecular coding to enable ultra‑sensitive (0.01% allele‑frequency) detection of >100 genetic targets in a single, automated workflow.
Opportunities
Expansion of mdPCR‑based panels into additional cancer types, NIPT, and infectious disease monitoring; strategic partnerships for international market entry.
Risk Factors
Regulatory approval beyond Taiwan, reimbursement challenges, and competition from NGS‑based liquid‑biopsy platforms.
Competitive Landscape
Competes with Guardant Health, Roche, and Illumina; differentiates through lower‑cost, high‑multiplex mdPCR technology with rapid, automated workflow.